Home › Research › TREM2 and immune genetics
Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease
Bekris LM, Khrestian M, Dyne E, Shao Y, Pillai JA, Rao SM, Bemiller SM, Lamb B et al.. Journal of neuroimmunology, 2018-03-20
Topic: Brain proteins, microglia and lab models
Plain-language summary
Alzheimer's disease (AD) has been genetically and pathologically associated with neuroinflammation. Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor involved in innate immunity. TREM2 rare protein coding genetic variants have been linked to AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bekris, L. M., Khrestian, M., Dyne, E., Shao, Y., Pillai, J. A., Rao, S. M., et al. (2018). Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. Journal of neuroimmunology. https://doi.org/10.1016/j.jneuroim.2018.03.003
Vancouver
Bekris LM, Khrestian M, Dyne E, Shao Y, Pillai JA, Rao SM, et al. Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. Journal of neuroimmunology. 2018. doi:10.1016/j.jneuroim.2018.03.003. PMID: 29685286.
BibTeX
@article{bekris2018-29685286,
author = {Bekris, L. M. and Khrestian, M. and Dyne, E. and Shao, Y. and Pillai, J. A. and Rao, S. M. and Bemiller, S. M. and Lamb, B. and others},
title = {{Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease}},
journal = {Journal of neuroimmunology},
year = {2018},
doi = {10.1016/j.jneuroim.2018.03.003},
pmid = {29685286},
url = {https://doi.org/10.1016/j.jneuroim.2018.03.003}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor involved in innate immunity.
- TREM2 rare protein coding genetic variants have been linked to AD.
- A soluble TREM2 (sTREM2) cleavage product is elevated in AD.
- It is unclear whether there is a relationship between elevated sTREM2 and markers of inflammation.
Why it matters
This study notes that a soluble cleavage product of TREM2 is elevated in Alzheimer's disease and asks whether it relates to markers of inflammation. It is about biomarkers and does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neuroimmunology) |
| Journal's citation record | 2 / 4 | Journal of Neuroimmunology: journal h-index 192 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 99 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.9 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 12 other studies in this library |
| Still being cited | 2 / 4 | Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author James B. Leverenz: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Cleveland Clinic: institution h-index 1,139 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29685286) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jneuroim.2018.03.003
- PubMed: 29685286
- Original source →
- Free full text: Journal of Neuroimmunology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 36.
Later studies that cite this one
12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.